Core Insights - Company has established a comprehensive global network covering R&D, manufacturing, marketing, and services, laying a solid foundation for ongoing internationalization [2][4] - The six major product lines, including monitors, anesthesia systems, ventilators, defibrillators, blood cell analyzers, and ultrasound imaging devices, rank among the top three in global markets [2][4] - Company's products have been adopted by 87 out of the top 100 hospitals globally as per Newsweek, demonstrating strong market presence [2][4] Financial Performance - By June 30, 2025, products will be sold in over 190 countries and regions, with overseas revenue expected to account for approximately 45% of total revenue in 2024 [2][4] - Revenue from the European and American markets is projected to exceed RMB 5.5 billion in 2024, representing 15% of total revenue for that year [5] Market Position and Strategy - Company has successfully penetrated numerous top-tier medical institutions known for strict procurement standards, reflecting its international leadership in technological innovation, product reliability, and clinical application value [5] - In the U.S., the company has covered about 80% of IDN medical systems and over 2,100 IDN hospitals, with nearly 35% of these hospitals using two or more product combinations [5] - The company has also entered the top 30 hospitals in the U.S. and over 660 European teaching hospitals, positioning itself as a key player in the global healthcare market [5] Growth Opportunities - The accelerating trends in medical digitization, chronic disease management, home care, and aging population are driving demand for smart monitoring, precise diagnostics, and minimally invasive treatments in the European and American markets [5] - These trends provide significant growth opportunities for the company to enhance penetration in high-end medical systems and optimize its product structure [5]

去年年末的时候，一篇关于日本90年代医疗崩坏的文章关注度颇高，后来甚至一度被制作成视频在各大社交媒体传播。作为曾经的日本医疗行业从业者，后 来又在研究医学新闻，看到文章的第一感觉是熟悉又陌生。不是说医疗崩坏这个话题在日本不存在，而是那篇文章对于日本医疗体制的表述存在着许多常识 性错误和文字上的误导，并且对于不熟悉整个日本的医疗制度的人来说，日本的医疗制度本身就存在着很多不同于中国的制度设计，完全按照中国的制度逻 辑去理解日本的医疗体制的话，并无多少益处。 这篇文章将对所谓的"九十年代日本医疗崩溃"进行事实核查。在此基础上我还发现所谓的高龄化导致医疗费暴涨的叙事其实从数据上就可以反驳，只可惜到 目前为止，整体舆论都还是对这一论调深信不疑。 一、90年代日本的公共卫生现状 文章开篇，作者提到"仅5年时间，全国65岁以上病患数就从不足200万暴涨至360万。" 或许有这个可能，但"暴涨"这个表述非常具有误导性。疾病本身也分慢性病和急性病。人随着年龄的增长，患病的概率也会增加。而高龄者罹患的疾病大多 是慢性病，除非传染性极强的疾病，不然病患数量一般都会在一个可预测的范围内，不可能会出现所谓的"暴涨"的情况。也就是说， ...